|
To further expand the current achievements in clinical cancer proteogenomic discoveries and infrastructure, NCI is soliciting applications for the reissuance of its Clinical Proteomic Tumor Analysis Consortium (CPTAC) program.
Three Funding Opportunity Announcements (FOAs), the first being of particular interest to the data science community, are currently open to all qualified applicants, regardless of whether they participated in the previous issuance of the CPTAC program.
NCI conducted a pre-application webinar on May 17, 2021, for the three FOAs. Watch the webinar recording, views the slides, and read the FAQs on the FOA webpage.
- Proteogenomic Data Analysis Centers (PGDACs) for CPTAC (Clinical Trial Not Allowed)
- Description: PGDAC awardees will be expected to develop computational tools for data analysis, data integration, and visualization and apply these tools to CPTAC data. The tools and approaches proposed for PGDACs should be suitable for analyses and meaningful interpretations of data derived from diverse types of samples (such as clinical specimens, cultured cells, and animal models of human cancers).
- Application Due Date: June 30, 2021
- Letter of Intent Due Date: 30 days prior to application due date
- Proteome Characterization Centers (PCCs) for CPTAC (Clinical Trial Not Allowed)
- Description: PCC awardees will be expected to work as an interactive group and use various standardized proteomic analysis technologies for the systematic and comprehensive proteome-wide characterization of defined sets of samples that will be genomically characterized.
- Application Due Date: June 30, 2021
- Letter of Intent Due Date: 30 days prior to application due date
- Proteogenomic Translational Research Centers (PTRCs) for CPTAC (Clinical Trial Not Allowed)
- Description: PTRCs are intended to function as an interactive group focused on applying standardized state-of-the-art proteomic and genomic approaches to understand tumor biology in clinically relevant research projects related to treatment response. Projects should focus on the proteogenomic aspects of understanding drug response and resistance by generating and testing hypotheses using preclinical cancer models and/or human cancer samples, followed by validation using human biospecimens from clinical trials.
- Application Due Date: July 30, 2021
- Letter of Intent Due Date: 30 days prior to application due date
|
